摘要
目的:对比老年女性表皮生长因子受体(EGFR)基因突变阳性的晚期肺腺癌患者使用不同治疗方案的效果和安全性。方法:回顾性分析近10年收治的EGFR基因检测阳性的老年晚期肺腺癌女性患者43例,根据治疗方案的不同分为对照组(n=21)与观察组(n=22)。对照组采用单药培美曲塞化疗方案,观察组采用吉非替尼治疗方案,对比分析两组患者的治疗效果与安全性。结果:观察组总有效率显著高于对照组,差异有统计学意义(P<0.05);随访后,观察组存活率明显高于对照组,差异有统计学意义(P<0.05)。结论:在治疗EGFR基因突变阳性老年女性晚期肺腺癌患者中应用吉非替尼治疗方案效果尤为显著,具有耐受性低且不良反应少等优势,可有效缓解患者的临床症状,提高治疗效果,有助于改善老年女性患者的生存质量。
Objective:Comparison of efficacy and safety of different treatment regimens in elderly female patients with advanced lung adenocarcinoma with EGFR gene mutation positive.Methods:Retrospective analysis forty-three elderly women with advanced lung adenocarcinoma who had positive EGFR gene detection in hospital during the past ten years.They were divided into control group ( n =21) and observation group ( n =22).Patients were treated with pemetrexed alone in control group,while patients were treated with gefitinib in observation group.The therapeutic effect and safety of the two groups were compared and analyzed.Results:The total effective rate of the observation group was significantly higher than that of the control group ( P <0.05),and the survival rate of the observation group was significantly higher than another group after one year of follow-up ( P <0.05).Conclusion:Gefitinib is especially effective in the treatment of advanced lung adenocarcinoma in elderly women with EGFR gene mutation positive.It has the advantages of low tolerance and less adverse reactions.It can effectively alleviate the clinical symptoms,improve the treatment effect,help to improve the quality of life of elderly women patients.
作者
燕丽香
李源
刘洋
陈文彰
YAN Lixiang;LI Yuan;LIU Yang;CHEN Wenzhang(Beijing Shijingshan Hospital,Beijing 100043,China)
出处
《临床医药实践》
2019年第7期499-500,534,共3页
Proceeding of Clinical Medicine
